These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 18032928)

  • 1. Reactive oxygen species contribute to cell killing and P-glycoprotein downregulation by salvicine in multidrug resistant K562/A02 cells.
    Cai Y; Lu J; Miao Z; Lin L; Ding J
    Cancer Biol Ther; 2007 Nov; 6(11):1794-9. PubMed ID: 18032928
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cytotoxicity, apoptosis induction and downregulation of MDR-1 expression by the anti-topoisomerase II agent, salvicine, in multidrug-resistant tumor cells.
    Miao ZH; Tang T; Zhang YX; Zhang JS; Ding J
    Int J Cancer; 2003 Aug; 106(1):108-15. PubMed ID: 12794765
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PHII-7 inhibits cell growth and induces apoptosis in leukemia cell line K562 as well as its MDR- counterpart K562/A02 through producing reactive oxygen species.
    Peng H; Yuan X; Shi R; Wei X; Ren S; Yan C; Ding Y; Lin Y; Fan D; Yang M; Zhang Y; Xiong D
    Eur J Pharmacol; 2013 Oct; 718(1-3):459-68. PubMed ID: 23911883
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transcription factor c-Jun activation represses mdr-1 gene expression.
    Miao ZH; Ding J
    Cancer Res; 2003 Aug; 63(15):4527-32. PubMed ID: 12907627
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reactive oxygen species elicit apoptosis by concurrently disrupting topoisomerase II and DNA-dependent protein kinase.
    Lu HR; Zhu H; Huang M; Chen Y; Cai YJ; Miao ZH; Zhang JS; Ding J
    Mol Pharmacol; 2005 Oct; 68(4):983-94. PubMed ID: 16024664
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of salvicine-resistant lung adenocarcinoma A549/SAL cell line.
    Miao ZH; Tong LJ; Zhang JS; Han JX; Ding J
    Int J Cancer; 2004 Jul; 110(5):627-32. PubMed ID: 15146550
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of imatinib and 5-bromotetrandrine on the reversal of multidrug resistance of the K562/A02 cell line.
    Chen BA; Shan XY; Chen J; Xia GH; Xu WL; Schmit M
    Chin J Cancer; 2010 Jun; 29(6):591-5. PubMed ID: 20507731
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of thiosemicarbazone-containing compounds with potent anti-proliferation activity against drug-resistant K562/A02 cells.
    Gu X; Li X; Guan M; Jiang C; Song Q; Sun N; Zou Y; Zhou Q; Chen J; Qiu J
    Bioorg Med Chem Lett; 2020 Dec; 30(24):127638. PubMed ID: 33132117
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modulation of P-glycoprotein activity by the substituted quinoxalinone compound QA3 in adriamycin-resistant K562/A02 cells.
    Sun LR; Zhong JL; Cui SX; Li X; Ward SG; Shi YQ; Zhang XF; Cheng YN; Gao JJ; Qu XJ
    Pharmacol Rep; 2010; 62(2):333-42. PubMed ID: 20508289
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Salvicine inactivates beta 1 integrin and inhibits adhesion of MDA-MB-435 cells to fibronectin via reactive oxygen species signaling.
    Zhou J; Chen Y; Lang JY; Lu JJ; Ding J
    Mol Cancer Res; 2008 Feb; 6(2):194-204. PubMed ID: 18314480
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessment of Thiosemicarbazone-Containing Compounds as Potential Antileukemia Agents against P-gp Overexpressing Drug Resistant K562/A02 Cells.
    Gu X; Guan M; Jiang C; Song Q; Li X; Sun N; Chen J; Qiu J
    Chem Biodivers; 2021 Feb; 18(2):e2000775. PubMed ID: 33314614
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sodium azulene sulfonate reverses multidrug resistance in K562/A02 cells.
    Wang Z; Zhou N; Zhao J; Zhang X
    Cell Mol Biol (Noisy-le-grand); 2019 Sep; 65(7):105-110. PubMed ID: 31880526
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aromatic heterocyclic esters of podophyllotoxin exert anti-MDR activity in human leukemia K562/ADR cells via ROS/MAPK signaling pathways.
    Zhang L; Zhang Z; Chen F; Chen Y; Lin Y; Wang J
    Eur J Med Chem; 2016 Nov; 123():226-235. PubMed ID: 27484511
    [TBL] [Abstract][Full Text] [Related]  

  • 14. L1EPO, a novel podophyllotoxin derivative overcomes P-glycoprotein-mediated multidrug resistance in K562/A02 cell line.
    Chen H; Wang J; Zhang J; Wang Y; Cao B; Bai S; Yu PF; Bi W; Xie W
    Biol Pharm Bull; 2009 Apr; 32(4):609-13. PubMed ID: 19336892
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Salvicine triggers DNA double-strand breaks and apoptosis by GSH-depletion-driven H2O2 generation and topoisomerase II inhibition.
    Cai YJ; Lu JJ; Zhu H; Xie H; Huang M; Lin LP; Zhang XW; Ding J
    Free Radic Biol Med; 2008 Sep; 45(5):627-35. PubMed ID: 18582559
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro cytotoxicity of salvicine, a novel diterpenoid quinone.
    Qing C; Zhang JS; Ding J
    Zhongguo Yao Li Xue Bao; 1999 Apr; 20(4):297-302. PubMed ID: 10452112
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Effects of arsenic trioxide on expressions of vascular endothelial growth factor and P-glycoprotein in multidrug resistant leukemia cell line K562/A02].
    Liang H; Zhang Y; Zhang JD; Gu J; Ma L; Wang XL; Shen WG
    Zhong Xi Yi Jie He Xue Bao; 2007 Nov; 5(6):647-50. PubMed ID: 17997939
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Salvicine, a novel topoisomerase II inhibitor, exerts its potent anticancer activity by ROS generation.
    Meng LH; Ding J
    Acta Pharmacol Sin; 2007 Sep; 28(9):1460-5. PubMed ID: 17723179
    [TBL] [Abstract][Full Text] [Related]  

  • 19. DNA damage, c-myc suppression and apoptosis induced by the novel topoisomerase II inhibitor, salvicine, in human breast cancer MCF-7 cells.
    Lu HR; Meng LH; Huang M; Zhu H; Miao ZH; Ding J
    Cancer Chemother Pharmacol; 2005 Mar; 55(3):286-94. PubMed ID: 15592835
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antitumor effects of cytosine deaminase and thymidine kinase fusion suicide gene under the control of mdr1 promoter in mdr1 positive leukemia cells.
    Wang X; Ji C; Ma D; Zhao J; Hou M; Yu H; Zang S
    Leuk Lymphoma; 2007 Aug; 48(8):1600-9. PubMed ID: 17701592
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.